In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Impacts of mineralocorticoid receptor antagonists on mortality in heart failure patients with beta-blockers

Session Poster Session 2

Speaker Naoko P Kato

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : NP Kato (Linkoping,SE), K Kinugawa (Toyama,JP)

Authors:
NP Kato1 , K Kinugawa2 , 1Linkoping University, Department of Social and Welfare Studies - Linkoping - Sweden , 2University of Toyama, The Second Department of Internal Medicine - Toyama - Japan ,

Citation:

Introduction: Mineralocorticoid receptor antagonists (MRA) is an important drug for patients with heart failure with reduced ejection fraction (HFrEF).  Although beneficial impacts of MRA on the patient’s survival have been shown from landmark trials, Japanese registry data did not consistently support it.  Beta-blockers have a key role for MRA to provide beneficial effects.  In these Japanese studies ß-blockers might not be used enough to make MRA work.

Purpose: To examine impacts of MRA on mortality of the Japanese HFrEF patients treated with ß-blockers.

Methods: Of all consecutive patients who were hospitalized in the university hospital because of HF between 2002 and 2010, 144 patients with left ventricular EF (LVEF) =35% who were introduced ß-blockers in the hospital were analysed (age 60.1±15.0 years, male 78%, LVEF 27.0±5.9 %).  Follow-up period was 3-years.  Primary and secondary end points were all-cause death and cardiac death respectively. Data were collected from medical records. In order to examine impacts of MRA, Kaplan-Meier survival curve analysis and Cox regression analysis were performed.

Results: A prescription rate of MRA among the HFrEF patients increased from 45% in 2002 to 78% in 2010.  All of MRA at baseline were spironolactone and mean daily dosage was 28.5±13.2 mg.  Mean daily dosage of ß-blockers was 8.8±8.6 mg in the carvedilol equivalent dosage.  Patients treated with MRA (n=86) were likely to have higher NYHA class III or IV (56% vs. 41%), lower LVEF (27% vs. 29%) and lower systolic blood pressure (114 vs. 120 mmHg) compared with patients without MRA (n=58).  Dosage of loop diuretics in patients with MRA was higher than that in patients without MRA (31.2 mg vs. 19.8 mg in the furosemide equivalent dose, p<0.01) at baseline, but no significant differences were observed at the end of follow-up (32.5 mg vs. 24.4 mg).  After the follow-up, all-cause mortality in patients without MRA was significantly higher than patients with MRA (13% vs. 2.7%, p=0.03 by log-rank test).  In the Cox regression analysis after adjustment for NYHA class, systolic blood pressure and loop diuretics, the absence of MRA remained to predict higher all-cause mortality (hazard ratio=0.18, 95% confidence interval=0.04 to 0.94).  Meanwhile, no significant difference was observed in cardiac death (p = 0.17) between the two groups.

Conclusions: One of the MRA, spironolactone, reduces all-cause mortality among Japanese HFrEF patients treated with ß-blockers.  Our finding emphasizes an importance of ß-blockers under the MRA treatment in HFrEF patients.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are